Riding High? Or Just a Puff of Smoke? A Closer Look at Medical Marijuana Inc.

This post was originally published on this site
 Shareholders of Medical Marijuana Inc. (NASDAQOTH:MJNA), a company traded over-the-counter, have had a stellar year. So far, shares are up over 300% since February of last year.

MJNA Chart

Is this spike simply investors trying to take advantage of the Election Day marijuana legalization in states like California, Maine, Massachusetts, and Nevada? Or have the fundamentals of this business dramatically changed? It’s time for a deeper dive.

two marijuana plants

Overview of the business

The first things investors should know about Medical Marijuana Inc. is that the company doesn’t actually manufacture and distribute medical marijuana. Instead, the company is broadly focused on the development and sale of hemp oil and hemp oil-derived products. Rather than manage this all under a single company, Medical Marijuana Inc. operates through its 8 partially or wholly owned subsidiaries:

1. HempMedsPX — Medical Marijuana’s primary distributor of hemp oil-based products

2. Wellness Managed Services — a management support and services company

3. Red Dice Holdings — a retail consumable products company

4. CanChew Biotechnologies — a licensing company based on the development of chewable cannabis therapies

5. Hempwire — a company focused on the marketing and distribution of hemp oil foods and nutritional supplements

6. Kannaway — a multi-level marketing company which distributes hemp oil-based products

7. HempVap — a company which manufactures a hemp oil vaporizer pen

8. HempMeds Brazil — a company which sells cannabis products to the Brazilian healthcare system

The company also owns sizable investments in KannaLife Sciences and Axim Biotechnologies.

Growth and earnings

While the company does not disclose which subsidiaries generate what percentage of overall revenue, the company does break out financials by U.S. Operations (including Puerto Rico), Kannaway LLC, and Wellness Managed Services. For the most recent quarter (3Q:16), U.S. Operations generated $1.6 million in revenues, Kannaway generated $600,000, and Wellness Managed Services generated no sales. In total, Medical Marijuana made around $2.2 million in sales and had a net loss of $3.8 million for the quarter. For comparison, in the third quarter of 2015, the company did a total of $1.8 million in sales and had a net loss of $5.7 million. While this represents sales growth of a healthy 22% year-over-year, earnings are still deeply negative.


Medical Marijuana currently has a market cap of roughly $463 million. While a PE for this company cannot be calculated due to negative earnings, if we annualized the $2.2 million in sales for the third quarter, Medical Marijuana Inc. would be trading at a whopping 53 times sales. In addition to the valuation, there are several other risks as well. Due to the negative earnings, the cash position of the company has been continuously falling. Moving from $1.2 million at the end of the first quarter, the cash position dwindled to $262,000 at the end of the third quarter. The company will need to raise more cash, either through an equity raise (diluting current shareholders) or by raising debt.

Debt, however, is already an issue. The company currently has total long-term liabilities sitting at $12 million and current liabilities at $5 million. For a company with negative earnings, this balance sheet seems unsustainable. In fact, with current liabilities well above net cash, I’d be surprised to see this company solvent in a year’s time.

Overall, while marijuana is sure to be a growing industry, I would look elsewhere for investing opportunities. As the company itself says in its SEC filings, “The Company is not in the business of selling or dispensing either recreational or medical marijuana, directly or indirectly, so long as marijuana remains a federally controlled substance.” I believe the confluence of a misleading name along with this year’s record number of marijuana legalizations have stoked investors’ desires to invest in the marijuana space. For myself, it is often a heady debate whether to buy or sell a stock, but the combination of an astronomical valuation along with a highly leveraged balance sheet make this one an easy call: Avoid at all costs.

David Liang has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.